OncoCyte Corporation (OCX)

Market Cap	94.95M
Revenue (ttm)	3.84M
Net Income (ttm)	-58.47M
Shares Out	28.60M
EPS (ttm)	-3.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,329
Open	3.220
Previous Close	3.260
Day's Range	3.185 - 3.320
52-Week Range	1.922 - 4.750
Beta	0.96
Analysts	Strong Buy
Price Target	5.42 (+63.25%)
Earnings Date	May 12, 2025

About OCX

OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCX
• Website: https://www.oncocyte.com

Financial Performance

In 2024, OncoCyte's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for OCX stock is "Strong Buy." The 12-month stock price forecast is $5.42, which is an increase of 63.25% from the latest price.

Price Target

$5.42

(63.25% upside)

Analyst Consensus: Strong Buy